X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
IDP-126 (clindamycin 1.2%, adapalene 0.15%, benzoyl peroxide 3.1%) gel has the potential to be the first of its kind fixed dose triple combination treatment for acne vulgaris by inhibiting bacterial protein synthesis.
Lead Product(s): Clindamycin Hydrochloride,Adapalene,Benzoyl Peroxide
Therapeutic Area: Dermatology Product Name: IDP-126
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2023
Details:
Clindamycin hydrochloride is a bacteriostatic which inhibits bacterial protein synthesis by binding to the 23S RNA of the 50S subunit of the ribosome.
Lead Product(s): Clindamycin Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: Cleocin-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023
Details:
Clindamycin is a well-established antibiotic used in treatment of severe infections, including staphylococcal bone and joint infections, chronic sinusitis and infections of the lower respiratory tract.
Lead Product(s): Clindamycin Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: Clindamycin-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Navamedic
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 23, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
